etoposide has been researched along with sobuzoxane in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (31.25) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Araya, S; Liu, YP; Nakamura, T | 1 |
| Azuma, Y; Kizaki, H; Onishi, Y | 1 |
| Andoh, T; Ariyoshi, Y; Hida, T; Nishizawa, M; Takahashi, T; Ueda, R | 1 |
| Ariyoshi, Y; Furue, H; Horiuchi, A; Kagami, Y; Kanamaru, A; Kano, Y; Masaoka, T; Naoe, T; Oguro, M; Ohno, R; Sampi, K; Shirakawa, S | 1 |
| Ohnishi, K | 1 |
| Fujimori, Y; Itoh, T; Kakishita, E; Mori, A; Nishimura, Y; Okada, M; Okamoto, T; Saheki, K; Takatsuka, H; Tamura, A; Wada, H; Yamada, S | 1 |
| Daibata, M; Hatakeyama, N; Hiroi, M; Kamioka, M; Miyoshi, I; Nemoto, Y; Taguchi, H | 1 |
| Kakishita, E; Mori, A; Okada, M; Okamoto, T; Takatsuka, H; Wakae, T | 1 |
| Akutsu, M; Inoue, K; Izumi, T; Kano, Y; Katano, S; Kobayashi, H; Masuda, Y; Muroi, K; Nagashima, T; Ohmine, K; Ozawa, K; Shirai, T; Takagi, S; Tsunoda, S; Ueda, M; Ueda, T | 1 |
| Blasiak, J; Poplawski, T | 1 |
| Abe, Y; Choi, I; Haji, S; Kiyasu, J; Ohshima, K; Suehiro, Y; Toyoda, K; Tsuda, M; Uike, N | 1 |
| Fukunaga, A; Inano, S; Kitano, T; Okamoto, Y; Shibata, S; Tabata, S; Takiuchi, Y; Yamamoto, K | 1 |
| Hojo, H; Ikeda, S; Koyama, D; Ohta, M; Sukegawa, M; Suzuki, M; Tsunoda, S | 1 |
| Fuji, S; Ohmoto, A | 1 |
| Fukuhara, Y; Harada, K; Irisawa, R; Kanzaki, A; Kato, Y; Mae, KI; Nagatani, T; Tsuboi, R; Umebayashi, Y | 1 |
1 review(s) available for etoposide and sobuzoxane
| Article | Year |
|---|---|
[Oral antitumor drugs for hematological malignancies].
Topics: Administration, Oral; Antineoplastic Agents; Cytarabine; Etoposide; Hematologic Neoplasms; Humans; Hydroxyurea; Leukemia-Lymphoma, Adult T-Cell; Piperazines; Prodrugs; Tretinoin | 1999 |
1 trial(s) available for etoposide and sobuzoxane
| Article | Year |
|---|---|
Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. MST-16 Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Piperazines; Recurrence; Salvage Therapy; Topoisomerase II Inhibitors | 1996 |
14 other study(ies) available for etoposide and sobuzoxane
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Arrest in late G2 or prophase of cell cycle induced by 4,4-(1,2-ethanediyl) bis (1-isobutoxycarbonyloxymethyl 2, 6-piperazinedione) (MST-16) in cultured L1210 cells.
Topics: Animals; Antineoplastic Agents; Cell Division; DNA; Drug Interactions; Etoposide; Flow Cytometry; G2 Phase; Leukemia L1210; Mice; Piperazines; Prophase; Tumor Cells, Cultured; Vincristine | 1992 |
bis(2,6-dioxopiperaxine) derivatives, topoisomerase II inhibitors which do not form a DNA cleavable complex, induce thymocyte apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cells, Cultured; Cycloheximide; Dactinomycin; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Gene Expression Regulation; Male; Mice; Mice, Inbred BALB C; Nucleic Acid Conformation; Piperazines; Razoxane; Thymus Gland; Topoisomerase I Inhibitors | 1994 |
Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Induction; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Proteins; Piperazines; Selection, Genetic; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Vincristine | 1996 |
Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Piperazines; Recurrence; Topoisomerase II Inhibitors | 2000 |
Detection of human herpesvirus 6 and JC virus in progressive multifocal leukoencephalopathy complicating follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain; Cyclophosphamide; DNA, Viral; Doxorubicin; Etoposide; Fatal Outcome; Female; Herpesviridae Infections; Herpesvirus 6, Human; Humans; Immunity, Cellular; Immunocompromised Host; JC Virus; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Follicular; Magnetic Resonance Imaging; Mitoxantrone; Nitrosourea Compounds; Papillomavirus Infections; Piperazines; Polymerase Chain Reaction; Prednisolone; Recurrence; Salvage Therapy; Vincristine; Vindesine; Virus Activation | 2001 |
Secondary acute promyelocytic leukemia in a patient with non-Hodgkin's lymphoma treated with VP-16 and MST-16.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Piperazines; Prednisolone; Remission Induction; Tretinoin; Vincristine | 2002 |
[MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Hydrocortisone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neutropenia; Piperazines; Salvage Therapy; Survival Rate; Thrombocytopenia; Vincristine | 2007 |
BCR/ABL downregulates DNA-PK(CS)-dependent and upregulates backup non-homologous end joining in leukemic cells.
Topics: Androstadienes; Cell Line, Tumor; Cell Survival; Comet Assay; DNA Breaks, Double-Stranded; DNA Repair; DNA-Activated Protein Kinase; Down-Regulation; Etoposide; Fusion Proteins, bcr-abl; Humans; Leukemia; Nuclear Proteins; Piperazines; Recombination, Genetic; Time Factors; Up-Regulation; Wortmannin | 2010 |
[Successful treatment with oral low-dose sobuzoxane and etoposide combined with rituximab in an elderly patient with HHV-8-negative primary effusion lymphoma-like lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Herpesvirus 8, Human; Humans; Lymphoma; Lymphoma, Primary Effusion; Male; Piperazines; Rituximab | 2014 |
Efficacy of salvage therapy with MTX-HOPE for elderly patients with heavily pretreated non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Hydrocortisone; Lymphoma, Non-Hodgkin; Male; Methotrexate; Piperazines; Salvage Therapy; Treatment Outcome; Vincristine | 2020 |
MTX-HOPE is a low-dose salvage chemotherapy for aged patients with relapsed or refractory non-Hodgkin lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Piperazines; Prognosis; Proportional Hazards Models; Recurrence; Salvage Therapy; Treatment Outcome; Vincristine | 2021 |
Clinical feasibility of oral low-dose etoposide and sobuzoxane for conventional chemotherapy-intolerant lymphoma patients.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Feasibility Studies; Humans; Lymphoma; Piperazines; Prospective Studies | 2021 |
Low-Dose MST-16/VP-16 Combination Chemotherapy in 9 Patients with Tumor Stage Mycosis Fungoides.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Etoposide; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Piperazines; Retrospective Studies; Skin Neoplasms | 2022 |